Trials / Conditions / Schizoaffective Disorders

Schizoaffective Disorders

13 registered clinical trials studyying Schizoaffective Disorders.

Status	Trial	Sponsor	Phase
Completed	Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patien NCT02307396	Technical University of Munich	Phase 4
Completed	Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) NCT01729650	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	N/A
Unknown	A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder NCT01389908	Shalvata Mental Health Center	N/A
Completed	Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia NCT01082588	Massachusetts General Hospital	Phase 4
Completed	Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia NCT00847600	Sha'ar Menashe Mental Health Center	Phase 4
Completed	An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective NCT00526877	Johnson & Johnson Taiwan Ltd	Phase 4
Terminated	Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder NCT00457899	AstraZeneca	Phase 3
Unknown	Supervised Treatment of Schizophrenia, a Randomized Controlled Trial. NCT00392249	Lady Reading Hospital, Pakistan	Phase 1 / Phase 2
Completed	Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine NCT00401973	Eli Lilly and Company	Phase 3
Completed	Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) NCT00453804	State University of New York - Upstate Medical University	Phase 4
Completed	Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects NCT00328978	AstraZeneca	Phase 3
Completed	Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. NCT00645502	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1
Completed	A Comparative Study of New Medications for Psychosis in Adolescents NCT00222495	University of Minnesota	N/A